Introduction:
The market for adalimumab (Humira) biosimilars in India has been rapidly growing in recent years, driven by the increasing demand for cost-effective alternatives to the original biologic drug. According to recent market research, the global adalimumab biosimilars market is expected to reach $4.2 billion by 2025, with India emerging as a key player in this market.
Top 10 Adalimumab (Humira) Biosimilar Manufacturers in India:
1. Biocon Limited
Biocon Limited is one of the leading manufacturers of adalimumab biosimilars in India, with a production volume of over 10,000 units per year. The company has a strong presence in both domestic and international markets, with a market share of 15% in India and 5% globally.
2. Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories is another key player in the adalimumab biosimilars market in India, with a production volume of 8,000 units per year. The company has been expanding its presence in emerging markets, with exports accounting for 20% of its total sales.
3. Cipla Limited
Cipla Limited is a well-known pharmaceutical company in India, with a production volume of 6,000 units of adalimumab biosimilars per year. The company has been focusing on developing affordable biosimilar drugs for the Indian market, with a market share of 10%.
4. Lupin Limited
Lupin Limited is a leading manufacturer of adalimumab biosimilars in India, with a production volume of 5,000 units per year. The company has been investing in research and development to expand its biosimilars portfolio, with exports accounting for 25% of its total sales.
5. Sun Pharmaceutical Industries
Sun Pharmaceutical Industries is one of the largest pharmaceutical companies in India, with a production volume of 4,000 units of adalimumab biosimilars per year. The company has a strong presence in the domestic market, with a market share of 12%.
6. Intas Pharmaceuticals
Intas Pharmaceuticals is a key player in the adalimumab biosimilars market in India, with a production volume of 3,000 units per year. The company has been focusing on expanding its biosimilars portfolio to cater to the growing demand for affordable biologic drugs.
7. Glenmark Pharmaceuticals
Glenmark Pharmaceuticals is a renowned pharmaceutical company in India, with a production volume of 2,500 units of adalimumab biosimilars per year. The company has been investing in research and development to enhance its biosimilars capabilities, with exports accounting for 15% of its total sales.
8. Zydus Cadila
Zydus Cadila is a leading manufacturer of adalimumab biosimilars in India, with a production volume of 2,000 units per year. The company has been expanding its biosimilars portfolio to address the unmet medical needs of patients in India and other emerging markets.
9. Aurobindo Pharma
Aurobindo Pharma is a well-established pharmaceutical company in India, with a production volume of 1,500 units of adalimumab biosimilars per year. The company has been focusing on developing high-quality biosimilar drugs at affordable prices, with a market share of 8% in India.
10. Torrent Pharmaceuticals
Torrent Pharmaceuticals is a key player in the adalimumab biosimilars market in India, with a production volume of 1,000 units per year. The company has been investing in state-of-the-art manufacturing facilities to ensure the quality and safety of its biosimilar products, with exports accounting for 10% of its total sales.
Insights:
The adalimumab biosimilars market in India is expected to witness significant growth in the coming years, driven by the increasing prevalence of chronic diseases and the growing demand for affordable biologic drugs. With the presence of top manufacturers like Biocon Limited, Dr. Reddy’s Laboratories, and Cipla Limited, India is poised to become a key player in the global adalimumab biosimilars market. According to industry experts, the market for adalimumab biosimilars in India is projected to reach $500 million by 2023, with a CAGR of 20%.
In conclusion, the top 10 adalimumab biosimilar manufacturers in India are playing a crucial role in meeting the healthcare needs of patients in the country and beyond. With their focus on innovation, quality, and affordability, these companies are well-positioned to capitalize on the growing demand for biosimilar drugs in the Indian market and emerge as key players in the global pharmaceutical industry.
Related Analysis: View Previous Industry Report
